Clinical trial
Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal…
NCT00414440 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00414440 |
|---|---|
| Title | Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease |
| Official title | A Multicenter, Randomized, Placebo-controlled, Double-blind Study on the Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease (ESRD) in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Autosomal Dominant Polycystic Kidney Disease |
| Intervention type | Drug |
| Interventions | Placebo, Everolimus |
| Enrollment | 431 |
| Start date | Dec 1, 2006 |
| Primary completion | Oct 1, 2013 |
| Completion | Oct 1, 2013 |
| First posted | Dec 21, 2006 |
| Last update posted | Jan 14, 2015 |
| Countries | Austria, France, Germany |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: